New drug reverses severe fatty liver disease by repairing the gut
An experimental drug developed at Michigan Medicine has reversed a serious form of fatty liver disease in animal studies by targeting an unexpected source of liver damage: the gut.
MASH affects approximately 7% of the world's population. It is a severe form of fatty liver disease in which excess fat accumulates in the liver, causing inflammation and cellular damage. Over time, the condition can progress to cirrhosis, which involves extensive liver scarring, as well as liver cancer and liver failure. Although treatment options have improved in recent years, effective therapies remain limited.
Opens ScienceDaily in a new tab